Whitehawk Therapeutics, Inc. (WHWK)
| Market Cap | 182.93M +87.5% |
| Revenue (ttm) | n/a -72.5% |
| Net Income | -83.29M |
| EPS | -1.06 |
| Shares Out | 59.01M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,617 |
| Open | 3.100 |
| Previous Close | 3.080 |
| Day's Range | 3.100 - 3.100 |
| 52-Week Range | 1.970 - 5.495 |
| Beta | 0.97 |
| Analysts | Buy |
| Price Target | 7.71 (+148.84%) |
| Earnings Date | Nov 9, 2026 |
About WHWK
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
Financial Performance
In 2025, Whitehawk Therapeutics's revenue was $7.15 million, a decrease of -72.50% compared to the previous year's $25.98 million. Losses were -$20.60 million, -67.66% less than in 2024.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for WHWK stock is "Buy." The 12-month stock price target is $7.71, which is an increase of 148.84% from the latest price.
News
Whitehawk Therapeutics reports Q3 EPS (23c), consensus (24c)
Cash, cash equivalents and short-term investments as of September 30, were $169.7M as compared to $145.7M as of December 31, 2025. Cash is anticipated to fund operations into 2H 2028…
Whitehawk Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
On track to report initial Phase 1 data from HWK-007 and HWK-016 in 1H'27 Initiated Phase 1 trial for HWK-206 in the U.S., the third Whitehawk program to enter the clinic in the last 12 months; HWK-20...
Whitehawk Therapeutics Earnings release: Q3 2026
Whitehawk Therapeutics released its Q3 2026 earnings on November 9, 2026, summarizing the period's financial results.
Whitehawk Therapeutics Quarterly report: Q3 2026
Whitehawk Therapeutics has published its Q3 2026 quarterly earnings report on November 9, 2026.
Whitehawk Therapeutics presents real-world analyses of MUC16 in ovarian cancer
Whitehawk Therapeutics (WHWK) announced the presentation of two real-world analyses supporting mucin 16 as a durable therapeutic target and potential prognostic biomarker in ovarian cancer. These data...
Whitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC Target in Ovarian Cancer at IGCS 2026
MUC16 Expression Remained High and Stable Following Standard-of-Care Therapies, Supporting Its Potential Utility in Both Combination Approaches and Relapsed Settings High MUC16 Expression Was Associat...
Whitehawk Therapeutics initiated with a Buy at Stifel
Stifel initiated coverage of Whitehawk Therapeutics (WHWK) with a Buy rating and $9 price target The firm views linker-payload stability as the company’s “core differentiator.” Whitehawk antibody drug...
Whitehawk Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The company has transformed into a next-generation ADC developer, advancing three lead programs through phase I trials and expanding its pipeline via strategic collaborations. Data from the first two programs are expected in early 2027, supported by a strong cash position extending into late 2028.
Whitehawk Therapeutics presents PTK7 data at WCLC 2026
Whitehawk Therapeutics (WHWK) announced the presentation of two real-world analyses supporting protein tyrosine kinase 7, or PTK7, as a durable and clinically relevant ADC target in patients with pret...
Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026
PTK7 Expression Remained Stable Following Standard-of-Care Therapies, Supporting Its Relevance as a Target in Second- or Later-Line EGFR NSCLC Findings Reinforce the Scientific Rationale for HWK-007, ...
Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors
Former Incyte Executive Brings Extensive Oncology, Corporate Strategy, Business Development and Medical Affairs Experience MORRISTOWN, N.J., Sept. 10, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc....
Whitehawk Therapeutics to Participate in Upcoming Investor Conferences
MORRISTOWN, N.J., Sept. 2, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology ...
Whitehawk Therapeutics Earnings release: Q2 2026
Whitehawk Therapeutics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Whitehawk Therapeutics Quarterly report: Q2 2026
Whitehawk Therapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.
Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
Phase 1 trials for HWK-007 and HWK-016 continue to enroll; the Phase 1 trial for HWK-206 is on track to initiate in Q3 2026 Cash, cash equivalents and short-term investments of $190.0 million as of Ju...
Whitehawk Therapeutics Slides: Corporate presentation
Whitehawk Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 5, 2026.
Whitehawk Therapeutics initiated with an Outperform at Leerink
Leerink initiated coverage of Whitehawk Therapeutics (WHWK) with an Outperform rating and $9 price target
Whitehawk, Biocytogen collaborate for bispecific antibody ADC development
Biocytogen and Whitehawk Therapeutics (WHWK) announced a global collaboration to develop bispecific antibody-drug conjugates. Biocytogen will provide access to up to five bispecific antibodies using i...
Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development
BOSTON & MORRISTOWN, N.J.--(BUSINESS WIRE)-- #ADC--Biocytogen (SSE: 688796; HKEX: 02315) and Whitehawk Therapeutics, Inc. (“Whitehawk,” Nasdaq: WHWK) today announced a global collaboration to develop ...
Whitehawk Therapeutics initiated with a Buy at B. Riley
B. Riley analyst Yuan Zhi initiated coverage of Whitehawk Therapeutics (WHWK) with a Buy rating and $10 price target Whitehawk is a clinical-stage oncology company advancing a three-asset, antibody-dr...
Whitehawk Therapeutics Transcript: AGM 2026
The meeting addressed three proposals, all of which passed, including director elections, executive compensation, and auditor ratification. No stockholder questions were received, and final voting results will be filed on Form 8-K.
Whitehawk Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
Three ADCs are advancing, with two in clinical trials and a third entering in Q3 2024, supported by unique linker technology and a recent $87.5M financing. The pipeline targets PTK7, MUC16, and SEZ6, aiming for high efficacy and improved tolerability, with data updates expected in 2027.
Whitehawk Therapeutics presents real-world analysis on SEZ6
Whitehawk Therapeutics (WHWK) announced the presentation of a real world analysis supporting the therapeutic potential of targeting seizure related homolog protein 6 with a next-generation ADC for the...
Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
SEZ6 expression exceeds that of approved and emerging ADC targets in SCLC SEZ6 expression is positively correlated with DLL3 expression across neuroendocrine carcinomas, indicating potential for com...
Whitehawk Therapeutics Registration statement: Registration filing
Whitehawk Therapeutics filed a registration statement on May 29, 2026, providing details about a securities offering with the SEC.